Pharma companies directory 2026

Pharmaceutical Companies in the Netherlands

The Dutch medicines market is small in pack terms and unusually strict on value: Zorginstituut Nederland can keep a product out of the basic package, and every health insurer now runs a preference list that can erase a generic brand overnight.

Zorginstituut’s GIP databank put extramural medicine spending at €5.7 billion in 2024, up 7.3%, for 11.8 million users. NZa’s wider pharmacy-plus-medicine series landed near €5.59 billion the same year. Those are modest numbers next to France or Italy, yet Leiden, Utrecht and Amsterdam host a specialty and gene-therapy cluster — Pharming, uniQure, Synthon, InnoGenerics, Astellas Europe, Byondis, Merus, Janssen’s vaccine unit — that punches far above the domestic P&L. CBG-MEB is the competent authority beside the EMA. VWS sets maximum prices under the Wet geneesmiddelenprijzen and decides, after a ZiN advice, whether a costly product enters the basispakket or sits in the sluis (lock) while a financial arrangement is negotiated. Parallel export from Dutch pharmacies into higher-priced neighbours is a chronic supply headache. BioNixus uses the roster below when a client needs to know who manufactures here, who commercialises here, and which insurer preference cycle will decide generic share.

Updated September 2026 · College ter Beoordeling van Geneesmiddelen (CBG-MEB) — authorised medicines and licensed manufacturers as of September 2026 · 18 named accounts

Request a proposal for the Netherlands Browse the 18 companies

€5.7bn

Extramural medicine expenditure in 2024, GIP databank / Zorginstituut (+7.3%)

11.8m

People who used an extramural medicine in 2024, GIP databank

€5.59bn

NZa 2024 total for medicines plus public-pharmacy care (provisional)

All

Health insurers running preferentiebeleid since 2024, VWS evaluation

Named accounts

Top pharmaceutical companies in the Netherlands

Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against College ter Beoordeling van Geneesmiddelen (CBG-MEB) — authorised medicines and licensed manufacturers (as of 2026-09-04).

#	Company	HQ	Type	Therapeutic focus	Notes
01	Pharming Group	Leiden	Local	Rare disease (hereditary angioedema), specialty biologics	Leiden-listed rare-disease company; a type case of Dutch specialty that sells globally while still running its commercial and medical core from the Bio Science Park.
02	uniQure	Amsterdam	Local	Gene therapy manufacturing and development	Amsterdam gene-therapy house whose Lexington and Dutch sites matter more as a European ATMP plant than as a large Dutch prescriber brand.
03	Synthon	Nijmegen	Local	Complex generics, finished-dose development, partnerships	Privately held developer that licenses products to commercial partners; Dutch and foreign generic labels often start from a Nijmegen dossier.
04	InnoGenerics	Leiden	Local	Essential-medicine manufacturing, former Teva site	State-backed restart of the old Leiden Teva plant, created to keep Dutch production of essential generics after Teva’s withdrawal.
05	Astellas Pharma Europe	Leiden	MNC	Oncology, urology, transplantation, European HQ functions	Japanese group’s European hub on the Leiden park; a reminder that “Dutch pharma” is often a regional headquarters, not only a local P&L.
06	Byondis	Nijmegen	Local	Antibody-drug conjugates, oncology biologics	Independent spin from the old Organon/MSD Oss-Nijmegen tradition; ADC pipeline work rather than a broad primary-care book.
07	Merus	Utrecht	Local	Bispecific antibodies in oncology	Utrecht-listed biotech whose commercial story is still mostly partner and US-trial driven, but whose HQ sits inside the Dutch specialty cluster.
08	Janssen Vaccines & Prevention	Leiden	MNC	Viral-vector vaccines, Leiden manufacturing and R&D	J&J’s Leiden vaccine unit; a manufacturing and science site rather than a large community-pharmacy detailing operation.
09	HAL Allergy	Leiden	Local	Allergen immunotherapy, diagnostics	Specialist manufacturer of allergy vaccines, typical of the Leiden park’s mid-size industrial layer beneath the listed biotechs.
10	Sandoz Nederland	Almere	MNC	Generics and biosimilars under insurer preference	The affiliate that lives or dies on preferentiebeleid: winning a Zilveren Kruis or VGZ designation can swing national generic share in a quarter.
11	Pfizer Nederland	Capelle aan den IJssel	MNC	Vaccines, oncology, rare disease, inflammation	Innovator affiliate whose costly launches go through ZiN and, often, the sluis before any GP ever writes a script.
12	Novartis Nederland	Amsterdam	MNC	Cardiology, oncology, immunology, ophthalmology	Specialty affiliate; package decisions and hospital arrangements matter more here than a primary-care field force.
13	Roche Nederland	Woerden	MNC	Oncology, haematology, neuroscience, diagnostics	Hospital and lock-procedure regular; ZiN cost-effectiveness questions arrive before a Dutch oncologist can initiate at scale.
14	Medicines Evaluation Board (CBG-MEB)	Utrecht	Government	National authorisation, shortages, pharmacovigilance	Competent authority. Shortage and parallel-export notifications sit on this desk beside classical variation and DCP work.
15	Zorginstituut Nederland	Diemen	Government	Pakket advice, cost-effectiveness, GIP databank	The NICE-like gate for expensive extras. A negative or conditional advice is the event that sends a product into the sluis or out of the package.
16	Ministerie van Volksgezondheid, Welzijn en Sport (VWS)	The Hague	Government	Wgp maximum prices, sluis, financial arrangements, package decisions	Takes ZiN’s advice and holds the lock. Also sets the four-country Wgp ceiling that keeps Dutch list prices among Europe’s lowest.
17	Zilveren Kruis	Leiden	Operator	Largest insurer preference lists for outpatient generics	Achmea label whose preferentiebeleid designations are watched as a leading indicator for the other insurers’ annual cycles.
18	Brocacef Groep	Maarssen	Distributor	Wholesale and pharmacy formula serving community pharmacies	Leading wholesaler-retail combination; the physical route for preference products once an insurer has named them.

Primary research

These are the pharmaceutical companies accounts we study in the Netherlands

Need account-level or SKU-level data for a brand in the Netherlands? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

Planning research in Netherlands?

Primary research, market access & HEOR. Proposals within 48 hours.

Top healthcare market research companies in the Netherlands (2026)

How the market is structured

Package decisions, insurer preference and hospital lock procedures

CBG-MEB issues or recognises the marketing authorisation. Reimbursement is a different door. Most established outpatient products fall under the Geneesmiddelenvergoedingssysteem: they are clustered and reimbursed at a reference limit. Insurers — Zilveren Kruis, VGZ, CZ, Menzis and the smaller labels — then designate a preferred product inside many clusters. Since 2024 every insurer does this. A manufacturer that is not preferred can still be prescribed, but the patient often pays the difference, which in practice kills share. Expensive extras sit outside that machine. ZiN advises VWS on whether the product belongs in the basispakket; if the budget impact is large, VWS can lock it in the sluis until a financial arrangement is signed. Hospital intramural medicines have their own expensive-drug negotiations with the same ministry. Parallel trade is the other Dutch peculiarity: low Wgp ceilings and a trading culture make the Netherlands a source country, which is why shortages and export notifications keep landing on CBG and KNMP desks. Community pharmacies are independent or grouped under formulas such as Brocacef’s partners; they dispense what the insurer prefers unless a medical exception is documented.

Local

Dutch specialty and manufacturing names — rare disease, gene therapy, complex generics, essential-medicine restart — clustered on the Leiden, Utrecht and Nijmegen parks.

Pharming Group
uniQure
Synthon
InnoGenerics
Byondis
Merus
HAL Allergy

Multinational

European hubs and commercial affiliates whose Dutch sales wait on ZiN and VWS, plus Sandoz competing for insurer preference rather than for GP brand loyalty.

Astellas Pharma Europe
Janssen Vaccines & Prevention
Sandoz Nederland
Pfizer Nederland
Novartis Nederland
Roche Nederland

Regional

Benelux or German generics and specialty houses that appoint a Dutch MA holder and then live or die on the same preference and sluis rules as locals.

Distributors & importers

CBG, ZiN and VWS in sequence, the four large insurers’ preference machines, and wholesaler-pharmacy groups that dispense whatever those lists name.

Medicines Evaluation Board (CBG-MEB)
Zorginstituut Nederland
Ministerie van Volksgezondheid, Welzijn en Sport (VWS)
Zilveren Kruis
Brocacef Groep

Market structure

Preferentiebeleid is not a tender, and the sluis is not HTA

Insurer preference is a reimbursement designation inside a GVS cluster. It is not a hospital tender and it is not a quality ranking. The designated product is the one the insured person can take without an extra bill. Losing that designation in January is a commercial event even if CBG registration and ZiN history are untouched.

The sluis is a ministerial waiting room. ZiN may already have written that the product is effective; VWS still withholds package entry until a price arrangement exists. Interviewing only ZiN methodologists and skipping VWS and the insurers produces a Dutch access map with the two gates that actually move money left blank.

What is moving

What is moving the pharmaceutical market in the Netherlands

Universal insurer preference

Every insurer now designates preferred generics. Annual cycles at Zilveren Kruis, VGZ, CZ and Menzis reshuffle pack share faster than any medical-representative plan can answer.

ZiN advice and the sluis

Costly extras stay locked until VWS has a financial arrangement. Time-to-package, not time-to-authorisation, is the Dutch launch metric that forecast models miss.

Specialty and ATMP cluster

Leiden and Amsterdam host gene therapy, rare-disease and vaccine plants whose customers are global. Domestic reimbursement is a side story for those sites and the main story for the affiliates.

Parallel export and Wgp ceilings

Low statutory maximum prices make the Netherlands a source country. Shortages and export notifications now sit inside every availability conversation with hospital pharmacists.

BioNixus fieldwork

How BioNixus studies pharmaceutical companies in the Netherlands

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in the Netherlands:

Insurer preference-cycle reconstructions for high-volume GVS clusters, comparing Zilveren Kruis designations with VGZ, CZ and Menzis in the same year.
Hospital-pharmacist and ZiN-experienced interviews in Amsterdam and Utrecht on sluis duration, arrangement terms and initiation after package entry.
Leiden Bio Science Park manufacturer conversations on export share versus Dutch demand, used when a client confuses a plant’s existence with domestic brand share.
Shortage and parallel-export incident reviews with hospital pharmacies, linking Wgp ceilings to reported holes in essential-medicine lines.

Questions

Frequently Asked Questions

Is the Netherlands a large domestic branded-generic market?

No. Extramural spend is a few billion euros, preference lists flatten brand premiums, and much of the industrial story is specialty manufacturing and European HQs. Teams that copy a Polish or Italian generic playbook will be surprised.

What does Zorginstituut Nederland decide?

Whether a medicine belongs in the basic insurance package, and on what conditions. It publishes the GIP expenditure series and writes the cost-effectiveness advice VWS uses before opening the sluis or listing an expensive extra.

How does preferentiebeleid change generic competition?

Insurers name one (or a short list of) reimbursed products per cluster. Patients who want another brand usually pay extra. Sandoz, Teva-era leftovers and smaller labels therefore compete for the designation, not for the GP’s favourite colour of box.

Why do Dutch pharmacies export medicines in parallel?

Wgp ceilings keep official prices low relative to Germany and some Nordic markets, and the trading infrastructure exists. CBG and the inspectorate monitor notifications; hospital pharmacists still report holes on the shelf that started as legal export.

How does BioNixus research pharmaceutical companies in the Netherlands?

By interviewing ZiN-experienced consultants and hospital pharmacists in Amsterdam and Utrecht, reconstructing insurer preference cycles, mapping sluis and arrangement outcomes, and talking to Leiden-park manufacturers about capacity versus domestic demand.

Is this a ranked list of Dutch pharmaceutical companies?

Readers looking for a turnover ranking will not find one. Inclusion follows CBG records, ZiN dossiers and fieldwork, not a league table.

Sources

Data sources & methodology

This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in the Netherlands. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

Primary register: College ter Beoordeling van Geneesmiddelen (CBG-MEB) — authorised medicines and licensed manufacturers, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in the Netherlands, not size.

Zorginstituut Nederland GIP databank update for 2024 — €5.7bn extramural spend, 11.8m users
NZa key figures on medicines and public-pharmacy care, 2019–2024 (provisional 2024 total €5.59bn)
VWS evaluation of Wgp and preferentiebeleid; all insurers applying preference policy from 2024
BioNixus Netherlands ZiN, insurer-preference and Leiden-cluster fieldwork, 2023–2026

BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

48-hour proposal

Need brand and competitor data in the Netherlands?

Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

Planning research in Netherlands?

Primary research, market access & HEOR. Proposals within 48 hours.

Pharmaceutical Companies in the Netherlands

Top pharmaceutical companies in the Netherlands

These are the pharmaceutical companies accounts we study in the Netherlands

Planning research in Netherlands?

Package decisions, insurer preference and hospital lock procedures

Local

Multinational

Regional

Distributors & importers

Preferentiebeleid is not a tender, and the sluis is not HTA

What is moving the pharmaceutical market in the Netherlands

Universal insurer preference

ZiN advice and the sluis

Specialty and ATMP cluster

Parallel export and Wgp ceilings

How BioNixus studies pharmaceutical companies in the Netherlands

Related research and directories

Frequently Asked Questions

Data sources & methodology

Need brand and competitor data in the Netherlands?

Planning research in Netherlands?